PRV-015 in Gluten-free Diet Non-responsive Celiac Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

388

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

July 30, 2024

Study Completion Date

July 30, 2024

Conditions
Celiac Disease
Interventions
BIOLOGICAL

PRV-015

Fully human monoclonal antibody against interleukin 15 (IL-15)

OTHER

Placebo

Placebo

Trial Locations (38)

10032

Clinical Trial Site, New York

11235

Clinical Trial Site, Brooklyn

12553

Clinical Site, New Windsor

14401

Clinical Site, Uniontown

17007

Clinical Trial Site, Girona

19104

Clinical Site, Philadelphia

20815

Clinical Trial Site, Chevy Chase

24071

Clinical Site, León

25196

Clinical Trial Site, Lleida

27607

Clinical Site, Raleigh

28034

Clinical Site, Madrid

28041

Clinical Site, Madrid

28222

Clinical Site, Madrid

29405

Clinical Trial Site, North Charleston

32789

Clinical Site, Winter Park

33613

Clinical Site, Tampa

34748

Clinical Site, Leesburg

37212

Clinical Site, Nashville

41013

Clinical Site, Seville

43016

Clinical Trial Site, Dublin

48047

Clinical Site, Chesterfield

55905

Clinical Site, Rochester

60062

Clinical Trial Site, Northbrook

60637

Clinical Site, Chicago

75044

Clinical Site, Garland

78613

Clinical Trial Site, Cedar Park

80209

Clinical Site, Denver

84088

Clinical Site, West Jordan

90036

Clinical Site, Los Angeles

93003

Clinical Site, Ventura

98004

Clinical Site, Bellevue

98405

Clinical Site, Tacoma

02111

Clinical Site, Boston

07960

Clinical Site, Morristown

02886

Clinical Site, Warwick

L8S4K1

Clinical Site, Hamilton

1105 AZ

Clinical Site, Amsterdam

082211

Clinical Trial Site, Terrassa

All Listed Sponsors
lead

Provention Bio, a Sanofi Company

INDUSTRY

NCT04424927 - PRV-015 in Gluten-free Diet Non-responsive Celiac Disease | Biotech Hunter | Biotech Hunter